Differential Expression of HER-2/NEU Receptor of Invasive Mammary Carcinoma Between Caucasian and African American patients in the Detroit Metropolitan Area. Correlation with Overall Survival and Other Prognostic Factors
Tóm tắt
HER-2/neu overexpression in invasive mammary carcinoma is associated with more aggressive biologic behavior. Breast cancer in African American (AA) women has been associated with a shorter survival rate than that seen in Caucasians (C). This study evaluated the frequency of HER-2/neu overexpression in C compared to AA patients and the association of HER-2/neu expression with overall survival and other prognostic factors. A retrospective review of the SEER data of Karmanos Cancer Institute for patients with invasive mammary carcinoma was conducted between 1998 and 2001. Pathology reports and pathology slides were obtained for those patients with missing data. Available data and material on 608 patients were found. The median follow-up interval was 35 months with a range of 1–91 months. 46.7% of the study population was C while 53.3% was AA. The differential of HER-2/neu expression in C and AA was evaluated. The association of HER-2/neu expression and other prognostic factors with overall survival was carried out by univariate and multivariable analyses using Cox’s proportional hazards regression model. No statistically significant difference was found in HER-2/neu expression between C and AA patients. Overexpression of HER-2/neu did not correlate with decreased overall survival in this analysis. Breast cancer HER-2/neu expression in AA patients is not statistically different from that of Caucasians. HER-2/neu expression is not associated with overall survival. Among the other prognostic factors analyzed, ER status and histologic grade were not statistically significant.
Tài liệu tham khảo
NJ Bundred, Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27 (2001) 137-142
S Kaptain, LK Tan and B Chen, Her-2/neu and breast cancer. Diagn Mol Pathol 10 (2001) 139-152
PM Ravdin and GC Chamness, The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers – a review. Gene 159 (1995) 19-27
DJ Slamon, GM Clark, SG Wong, WJ Levin, A Ullrich and WL McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
JL Bernstein, L Lopez-Carrillo and L Wang, The epidemiology of Her-2/neu and P53 in breast cancer. Salud Publica Mex 41 (1999) S114-S123
RM Elledge, GM Clark, GC Chamness and CK Osborne, Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86 (1994) 705-712
MM Ameyaw, M Tayeb, N Thornton, G Folayan, M Tariq, A Mobarek, DA Evans, D Ofori-Adjei and HL McLead, Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet 47 (2002) 172-175
A Jukkola, R Bloigu, Y Soini, ER Savolainen, K Holli and G Blanco, c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer 37 (2001) 347-354
S Menard, A Balsari, P Casalini, E Tagliabue, M Campiglio, R Bufalino and N Cascinelli, HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 8 (2002) 520-525
MF Press, L Bernstein, PA Thomas, LF Meisner, JY Zhou, Y Ma, G Hung, RA Robinson, C Harris, A El-Naggar, DJ Slamon, RN Phillips, JS Ross, SR Wolman and KJ Flom, HER-2/neu gene amplification characterized by fluorescence hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15 (1997) 2894-2904
S Tsutsui, S Ohno, S Murakami, Y Hachitanda and S Oda, Prognostic value of c-erbB2 expression in breast cancer. J Surg Oncol 79 (2002) 216-223
JW Eley, HA Hill, VW Chen, DF Austin, MN Wesley, HB Muss, RS Greenberg, RJ Coates, P Correa and CK Redmond, Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA 272 (1994) 947-954
SA Joslyn and MM West, Racial differences in breast carcinoma survival. Cancer 88 (2000) 114-123
P Reynolds, S Hurley, M Torres, J Jackson, P Boyd and VW Chen, Use of coping strategies and breast cancer survival: results from the Black/White Cancer Survival Study. Am J Epidemiol 152 (2000) 940-949
A. Li, G Burton and J Glass, Breast cancer: a socioeconomic and racial comparison in northwest Louisiana. J La State Med Soc 153 (2001) 420-425
MS O’Malley, JA Earp, ST Hawley, MJ Schell, HF Mathews and J Mitchell, The association of race/ethnicity, socioeconomic status, and physician recommendation for mammography: who gets the message about breast cancer screening?. Am J Public Health 91 (2001) 49-54
N Breen, MN Wesley, RM Merrill and K Johnson, The relationship of socio-economic status and access to minimum expected therapy among female breast cancer patients in the National Cancer Institute Black-White Cancer Survival Study. Ethn Dis 9 (1999) 111-125
DP Rose and R Royak-Schaler, Tumor biology and prognosis in black breast cancer patients: a review. Cancer Detect Prev 25 (2001) 16-31
PG Moorman, BA Jones, RC Millikan, IJ Hall and B Newman, Race, anthropometric factors, and stage at diagnosis of breast cancer. Am J Epidemiol 153 (2001) 284-291
R Millikan, E DeVoto, EJ Duell, CK Tse, DA Savitz, J Beach, S Edmiston, S Jackson and B Newman, Dichlorodiphenyldichloroethene, polychlorinated biphenyls, and breast cancer among African-American and white women in North Carolina. Cancer Epidemiol Biomarkers Prev 9 (2000) 1233-1240
Q Gao, CA Adebamowo and J Fackenthal, Protein truncating BRCA1 and BRCA2 mutations in African women with pre-menopausal breast cancer. Hum Genet 107 (2000) 192-194
Q Gao, G Tomlinson, S Das, S Cummings, L Sveen, J Fackenthal, P Schumm and OI Olopade, Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet 107 (2000) 186-191
D Shen, Y Wu, M Subbarao, H Bhat, R Chillar and JV Vadgama, Mutation analysis of BRCA1 gene in African-American patients with breast cancer. J Natl Med Assoc 92 (2000) 29-35
J Dangel, J Wagner-Costalas, B Bove, L Vanderveer, M Itzen, M Daly and AK Godwin, Novel germline BRCA1 mutation (155del4) in an African American with early-onset breast cancer. Hum Mutat 14 (1999) 545
BE Wojcik, MK Spinks and SA Optenberg, Breast carcinoma survival analysis for African American and white women in an equal-access health care system. Cancer 82 (1998) 1310-1318
SC Bibb, The relationship between access and stage at diagnosis of breast cancer in African American and Caucasian women. Oncol Nurs Forum 28 (2001) 711-719
RG Roetzheim, EC Gonzalez, JM Ferrante, N Pal, DJ Durme Van and JP Krischer, Effects of health insurance and race on breast carcinoma treatments and outcomes. Cancer 89 (2000) 2202-2213
H Aziz, F Hussain, C Sohn, R Mediavillo, A Saitta, A Hussain, M Brandys, P Homel and M Rotman, Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Oncol 22 (1999) 436-440
SE Weiss, PI Tartter, S Ahmed, ST Brower, C Brusco, K Bossolt, JB Amberson and J Bratton, Ethnic differences in risk and prognostic factors for breast cancer. Cancer 76 (1995) 268-274
S Koduri, SA Fuqua and I Poola, Alterations in the estrogen receptor alpha mRNA in the breast tumors of African American women. J Cancer Res Clin Oncol 126 (2000) 291-297
T Haerslev and GK Jacobsen, c-erbB-2 oncoprotein is not an independent prognostic parameter in primary breast carcinoma. An immunohistochemical study. Apmis 102 (1994) 612-622